Simcere Pharmaceutical Group Enterprise Value:
559.25M for May 17, 2013Simcere Pharmaceutical Group Historical Enterprise Value Data
Pro Data ExportThere is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| May 17, 2013 | 559.25M |
| May 16, 2013 | 559.76M |
| May 15, 2013 | 560.27M |
| May 14, 2013 | 553.68M |
| May 13, 2013 | 552.16M |
| May 10, 2013 | 552.16M |
| May 9, 2013 | 551.14M |
| May 8, 2013 | 553.17M |
| May 7, 2013 | 551.14M |
| May 6, 2013 | 551.14M |
| May 3, 2013 | 551.14M |
| May 2, 2013 | 550.63M |
| May 1, 2013 | 550.13M |
| April 30, 2013 | 550.13M |
| April 29, 2013 | 548.61M |
| April 26, 2013 | 546.07M |
| April 25, 2013 | 545.56M |
| April 24, 2013 | 548.61M |
| April 23, 2013 | 549.11M |
| April 22, 2013 | 550.63M |
| April 19, 2013 | 553.68M |
| April 18, 2013 | 549.11M |
| April 17, 2013 | 552.16M |
| April 16, 2013 | 554.18M |
| April 15, 2013 | 554.69M |
| April 12, 2013 | 557.23M |
| April 11, 2013 | 557.23M |
| April 10, 2013 | 557.23M |
| April 9, 2013 | 555.70M |
| April 8, 2013 | 557.23M |
| April 5, 2013 | 556.72M |
| April 4, 2013 | 555.20M |
| April 3, 2013 | 553.68M |
| April 2, 2013 | 554.69M |
| April 1, 2013 | 550.63M |
| March 28, 2013 | 556.72M |
| March 27, 2013 | 554.18M |
| March 26, 2013 | 556.21M |
| March 25, 2013 | 551.65M |
| March 22, 2013 | 551.14M |
| March 21, 2013 | 551.14M |
| March 20, 2013 | 550.63M |
| March 19, 2013 | 543.54M |
| March 18, 2013 | 547.08M |
| March 15, 2013 | 544.04M |
| March 14, 2013 | 543.54M |
| March 13, 2013 | 547.59M |
| March 12, 2013 | 518.69M |
| March 11, 2013 | 558.75M |
| March 8, 2013 | 493.34M |
About Enterprise Value
Click "Learn More" below to see how YCharts calculates Enterprise Value.
Enterprise Value (EV) is a valuation metric alternative to traditional market capitalization that reflects the market value of an entire business. Like market cap, EV is a measure of what the market believes a company is worth. Enterprise value captures the cost of an entire business, including debt and equity. It is a sum of claims of all preferred shareholders, debt holders, security holders, common equity holders, and minority shareholders - unlike market cap, which only captures the total value of common equity securities.
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Learn More
SCR Enterprise Value Benchmarks
| Companies | |
|---|---|
| Acura Pharmaceuticals | 85.53M |
| Horizon Pharma | 93.39M |
| Sagent Pharmaceuticals | 387.16M |
SCR Enterprise Value Rankings
| Overall |
67th percentile 2478 of 7590 |
| Sector |
65th percentile 223 of 651 in Healthcare |
| Industry |
66th percentile 22 of 65 in Drug Manufacturers - Specialty & Generic |
SCR Enterprise Value Range, Past 5 Years
| Minimum | 187.18M | Oct 29 2008 |
| Maximum | 861.51M | May 28 2008 |
| Average | 525.82M |
